Treatment response in evaluable patients according to baseline platelet counts
. | SUMMIT . | . | CREST* . | |
|---|---|---|---|---|
| . | BPC less than 75 × 109/L . | BPC 75 × 109/L or greater . | BPC 75 × 109/L or greater . | |
| No. patients | 35 | 157 | 26 | |
| CR, no. (%) | 3 (9) | 15 (10) | 1 (4) | |
| PR, no. (%) | 8 (23) | 26 (17) | 9 (35) | |
| MR, no. (%) | 2 (6) | 12 (8) | 3 (12) | |
| Overall response (CR, PR, MR), no. (%) | 13 (37) | 53 (34) | 13 (50) | |
. | SUMMIT . | . | CREST* . | |
|---|---|---|---|---|
| . | BPC less than 75 × 109/L . | BPC 75 × 109/L or greater . | BPC 75 × 109/L or greater . | |
| No. patients | 35 | 157 | 26 | |
| CR, no. (%) | 3 (9) | 15 (10) | 1 (4) | |
| PR, no. (%) | 8 (23) | 26 (17) | 9 (35) | |
| MR, no. (%) | 2 (6) | 12 (8) | 3 (12) | |
| Overall response (CR, PR, MR), no. (%) | 13 (37) | 53 (34) | 13 (50) | |
BPC indicates baseline platelet count; CR, complete response; PR, partial response; and MR, minor response.
No patient in CREST receiving bortezomib 1.3 mg/m2 had a baseline platelet count less than 75 × 109/L.